Treatment by Cancer Type
------------------------

 NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) are posted with the latest update date and version number. 

[Acute Lymphoblastic Leukemia](https://www.nccn.org/guidelines/guidelines-detail?category=1&id=1410)

 Version: 2.2025 

[Acute Myeloid Leukemia](https://www.nccn.org/guidelines/guidelines-detail?category=1&id=1411)

 Version: 1.2026 

[Ampullary Adenocarcinoma](https://www.nccn.org/guidelines/guidelines-detail?category=1&id=1511)

 Version: 2.2025 

[Anal Carcinoma](https://www.nccn.org/guidelines/guidelines-detail?category=1&id=1414)

 Version: 4.2025 

[Basal Cell Skin Cancer](https://www.nccn.org/guidelines/guidelines-detail?category=1&id=1416)

 Version: 1.2026 

[B-Cell Lymphomas](https://www.nccn.org/guidelines/guidelines-detail?category=1&id=1480)

 Version: 3.2025 

[Biliary Tract Cancers](https://www.nccn.org/guidelines/guidelines-detail?category=1&id=1517)

 Version: 2.2025 

[Bladder Cancer](https://www.nccn.org/guidelines/guidelines-detail?category=1&id=1417)

 Version: 1.2025 

[Bone Cancer](https://www.nccn.org/guidelines/guidelines-detail?category=1&id=1418)

 Version: 1.2026 

[Breast Cancer](https://www.nccn.org/guidelines/guidelines-detail?category=1&id=1419)

 Version: 4.2025 

[Castleman Disease](https://www.nccn.org/guidelines/guidelines-detail?category=1&id=1518)

 Version: 2.2025 

[Central Nervous System Cancers](https://www.nccn.org/guidelines/guidelines-detail?category=1&id=1425)

 Version: 2.2025 

[Cervical Cancer](https://www.nccn.org/guidelines/guidelines-detail?category=1&id=1426)

 Version: 4.2025 

[Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma](https://www.nccn.org/guidelines/guidelines-detail?category=1&id=1478)

 Version: 3.2025 

[Chronic Myeloid Leukemia](https://www.nccn.org/guidelines/guidelines-detail?category=1&id=1427)

 Version: 1.2026 

[Colon Cancer](https://www.nccn.org/guidelines/guidelines-detail?category=1&id=1428)

 Version: 4.2025 

[Dermatofibrosarcoma Protuberans](https://www.nccn.org/guidelines/guidelines-detail?category=1&id=1430)

 Version: 1.2026 

[Esophageal and Esophagogastric Junction Cancers](https://www.nccn.org/guidelines/guidelines-detail?category=1&id=1433)

 Version: 4.2025 

[Gastric Cancer](https://www.nccn.org/guidelines/guidelines-detail?category=1&id=1434)

 Version: 3.2025 

[Gastrointestinal Stromal Tumors](https://www.nccn.org/guidelines/guidelines-detail?category=1&id=1507)

 Version: 1.2025 

[Gestational Trophoblastic Neoplasia](https://www.nccn.org/guidelines/guidelines-detail?category=1&id=1489)

 Version: 3.2025 

[Hairy Cell Leukemia](https://www.nccn.org/guidelines/guidelines-detail?category=1&id=1481)

 Version: 1.2026 

[Head and Neck Cancers](https://www.nccn.org/guidelines/guidelines-detail?category=1&id=1437)

 Version: 5.2025 

[Hepatobiliary Cancers](https://www.nccn.org/guidelines/guidelines-detail?category=1&id=1438)

 Version: 1.2023 

[Hepatocellular Carcinoma](https://www.nccn.org/guidelines/guidelines-detail?category=1&id=1514)

 Version: 1.2025 

[Histiocytic Neoplasms](https://www.nccn.org/guidelines/guidelines-detail?category=1&id=1502)

 Version: 1.2025 

[Hodgkin Lymphoma](https://www.nccn.org/guidelines/guidelines-detail?category=1&id=1439)

 Version: 2.2025 

[Kaposi Sarcoma](https://www.nccn.org/guidelines/guidelines-detail?category=1&id=1485)

 Version: 2.2026 

[Kidney Cancer](https://www.nccn.org/guidelines/guidelines-detail?category=1&id=1440)

 Version: 1.2026 

[Melanoma: Cutaneous](https://www.nccn.org/guidelines/guidelines-detail?category=1&id=1492)

 Version: 2.2025 

[Melanoma: Uveal](https://www.nccn.org/guidelines/guidelines-detail?category=1&id=1488)

 Version: 1.2025 

[Merkel Cell Carcinoma](https://www.nccn.org/guidelines/guidelines-detail?category=1&id=1444)

 Version: 1.2026 

[Mesothelioma: Peritoneal](https://www.nccn.org/guidelines/guidelines-detail?category=1&id=1513)

 Version: 2.2025 

[Mesothelioma: Pleural](https://www.nccn.org/guidelines/guidelines-detail?category=1&id=1512)

 Version: 2.2025 

[Multiple Myeloma](https://www.nccn.org/guidelines/guidelines-detail?category=1&id=1445)

 Version: 2.2026 

[Myelodysplastic Syndromes](https://www.nccn.org/guidelines/guidelines-detail?category=1&id=1446)

 Version: 2.2025 

[Myeloid/Lymphoid Neoplasms with Eosinophilia and Tyrosine Kinase Gene Fusions](https://www.nccn.org/guidelines/guidelines-detail?category=1&id=1505)

 Version: 2.2025 

[Myeloproliferative Neoplasms](https://www.nccn.org/guidelines/guidelines-detail?category=1&id=1477)

 Version: 2.2025 

[Neuroblastoma](https://www.nccn.org/guidelines/guidelines-detail?category=1&id=1520)

 Version: 1.2025 

[Neuroendocrine and Adrenal Tumors](https://www.nccn.org/guidelines/guidelines-detail?category=1&id=1448)

 Version: 2.2025 

[Non-Small Cell Lung Cancer](https://www.nccn.org/guidelines/guidelines-detail?category=1&id=1450)

 Version: 8.2025 

[Occult Primary](https://www.nccn.org/guidelines/guidelines-detail?category=1&id=1451)

 Version: 2.2025 

[Ovarian Cancer/Fallopian Tube Cancer/Primary Peritoneal Cancer](https://www.nccn.org/guidelines/guidelines-detail?category=1&id=1453)

 Version: 3.2025 

[Pancreatic Adenocarcinoma](https://www.nccn.org/guidelines/guidelines-detail?category=1&id=1455)

 Version: 2.2025 

[Pediatric Acute Lymphoblastic Leukemia](https://www.nccn.org/guidelines/guidelines-detail?category=1&id=1496)

 Version: 1.2026 

[Pediatric Aggressive Mature B-Cell Lymphomas](https://www.nccn.org/guidelines/guidelines-detail?category=1&id=1504)

 Version: 2.2025 

[Pediatric Central Nervous System Cancers](https://www.nccn.org/guidelines/guidelines-detail?category=1&id=1509)

 Version: 3.2025 

[Pediatric Hodgkin Lymphoma](https://www.nccn.org/guidelines/guidelines-detail?category=1&id=1498)

 Version: 2.2025 

[Penile Cancer](https://www.nccn.org/guidelines/guidelines-detail?category=1&id=1456)

 Version: 2.2025 

[Primary Cutaneous Lymphomas](https://www.nccn.org/guidelines/guidelines-detail?category=1&id=1491)

 Version: 3.2025 

[Prostate Cancer](https://www.nccn.org/guidelines/guidelines-detail?category=1&id=1459)

 Version: 2.2026 

[Rectal Cancer](https://www.nccn.org/guidelines/guidelines-detail?category=1&id=1461)

 Version: 3.2025 

[Small Bowel Adenocarcinoma](https://www.nccn.org/guidelines/guidelines-detail?category=1&id=1495)

 Version: 3.2025 

[Small Cell Lung Cancer](https://www.nccn.org/guidelines/guidelines-detail?category=1&id=1462)

 Version: 2.2026 

[Soft Tissue Sarcoma](https://www.nccn.org/guidelines/guidelines-detail?category=1&id=1464)

 Version: 1.2025 

[Squamous Cell Skin Cancer](https://www.nccn.org/guidelines/guidelines-detail?category=1&id=1465)

 Version: 1.2026 

[Systemic Light Chain Amyloidosis](https://www.nccn.org/guidelines/guidelines-detail?category=1&id=1467)

 Version: 1.2026 

[Systemic Mastocytosis](https://www.nccn.org/guidelines/guidelines-detail?category=1&id=1490)

 Version: 1.2025 

[T-Cell Lymphomas](https://www.nccn.org/guidelines/guidelines-detail?category=1&id=1483)

 Version: 2.2025 

[Testicular Cancer](https://www.nccn.org/guidelines/guidelines-detail?category=1&id=1468)

 Version: 2.2025 

[Thymomas and Thymic Carcinomas](https://www.nccn.org/guidelines/guidelines-detail?category=1&id=1469)

 Version: 2.2025 

[Thyroid Carcinoma](https://www.nccn.org/guidelines/guidelines-detail?category=1&id=1470)

 Version: 1.2025 

[Uterine Neoplasms](https://www.nccn.org/guidelines/guidelines-detail?category=1&id=1473)

 Version: 3.2025 

[Vaginal Cancer](https://www.nccn.org/guidelines/guidelines-detail?category=1&id=1521)

 Version: 5.2025 

[Vulvar Cancer](https://www.nccn.org/guidelines/guidelines-detail?category=1&id=1476)

 Version: 1.2025 

[Waldenström Macroglobulinemia/Lymphoplasmacytic Lymphoma](https://www.nccn.org/guidelines/guidelines-detail?category=1&id=1475)

 Version: 1.2026 

[Wilms Tumor (Nephroblastoma)](https://www.nccn.org/guidelines/guidelines-detail?category=1&id=1500)

 Version: 2.2025 

 
 The NCCN Guidelines are copyrighted by the NCCN. All rights reserved. NCCN Guidelines and illustrations (including algorithms) may not be reproduced in any form for any purpose without the express written permission of the NCCN. Permissions Requests Section. 


 # NCCN 2025 癌症治疗指南目录

## 概要总结

NCCN临床实践指南涵盖了67种癌症类型，按系统分类如下：

- **血液系统肿瘤**：15种（包括各类白血病、淋巴瘤、骨髓瘤等）
- **消化系统肿瘤**：11种（包括胃癌、结直肠癌、肝癌、胰腺癌等）
- **妇科肿瘤**：6种（包括宫颈癌、卵巢癌、子宫内膜癌等）
- **泌尿生殖系统肿瘤**：6种（包括前列腺癌、肾癌、膀胱癌等）
- **肺部肿瘤**：2种（非小细胞肺癌、小细胞肺癌）
- **皮肤肿瘤**：6种（包括黑色素瘤、基底细胞癌等）
- **头颈部肿瘤**：2种（头颈癌、甲状腺癌）
- **神经系统肿瘤**：3种（中枢神经系统癌症及儿科版本）
- **软组织及骨肿瘤**：4种（软组织肉瘤、骨癌等）
- **儿科肿瘤**：5种（儿科白血病、淋巴瘤等）
- **其他肿瘤**：7种（包括间皮瘤、神经内分泌肿瘤等）

## 详细指南列表

| 序号 | 癌症类型 | 版本 | 备注 |
|------|----------|------|------|
| 1 | [Acute Lymphoblastic Leukemia](https://www.nccn.org/guidelines/guidelines-detail?category=1&id=1410) | 2.2025 | 急性淋巴细胞白血病 |
| 2 | [Acute Myeloid Leukemia](https://www.nccn.org/guidelines/guidelines-detail?category=1&id=1411) | 1.2026 | 急性髓系白血病 |
| 3 | [Ampullary Adenocarcinoma](https://www.nccn.org/guidelines/guidelines-detail?category=1&id=1511) | 2.2025 | 壶腹部腺癌 |
| 4 | [Anal Carcinoma](https://www.nccn.org/guidelines/guidelines-detail?category=1&id=1414) | 4.2025 | 肛门癌 |
| 5 | [Basal Cell Skin Cancer](https://www.nccn.org/guidelines/guidelines-detail?category=1&id=1416) | 1.2026 | 基底细胞皮肤癌 |
| 6 | [B-Cell Lymphomas](https://www.nccn.org/guidelines/guidelines-detail?category=1&id=1480) | 3.2025 | B细胞淋巴瘤 |
| 7 | [Biliary Tract Cancers](https://www.nccn.org/guidelines/guidelines-detail?category=1&id=1517) | 2.2025 | 胆道癌 |
| 8 | [Bladder Cancer](https://www.nccn.org/guidelines/guidelines-detail?category=1&id=1417) | 1.2025 | 膀胱癌 |
| 9 | [Bone Cancer](https://www.nccn.org/guidelines/guidelines-detail?category=1&id=1418) | 1.2026 | 骨癌 |
| 10 | [Breast Cancer](https://www.nccn.org/guidelines/guidelines-detail?category=1&id=1419) | 4.2025 | 乳腺癌 |
| 11 | [Castleman Disease](https://www.nccn.org/guidelines/guidelines-detail?category=1&id=1518) | 2.2025 | 卡斯特曼病 |
| 12 | [Central Nervous System Cancers](https://www.nccn.org/guidelines/guidelines-detail?category=1&id=1425) | 2.2025 | 中枢神经系统癌症 |
| 13 | [Cervical Cancer](https://www.nccn.org/guidelines/guidelines-detail?category=1&id=1426) | 4.2025 | 宫颈癌 |
| 14 | [Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma](https://www.nccn.org/guidelines/guidelines-detail?category=1&id=1478) | 3.2025 | 慢性淋巴细胞白血病/小淋巴细胞淋巴瘤 |
| 15 | [Chronic Myeloid Leukemia](https://www.nccn.org/guidelines/guidelines-detail?category=1&id=1427) | 1.2026 | 慢性髓系白血病 |
| 16 | [Colon Cancer](https://www.nccn.org/guidelines/guidelines-detail?category=1&id=1428) | 4.2025 | 结肠癌 |
| 17 | [Dermatofibrosarcoma Protuberans](https://www.nccn.org/guidelines/guidelines-detail?category=1&id=1430) | 1.2026 | 隆突性皮肤纤维肉瘤 |
| 18 | [Esophageal and Esophagogastric Junction Cancers](https://www.nccn.org/guidelines/guidelines-detail?category=1&id=1433) | 4.2025 | 食管癌和食管胃结合部癌 |
| 19 | [Gastric Cancer](https://www.nccn.org/guidelines/guidelines-detail?category=1&id=1434) | 3.2025 | 胃癌 |
| 20 | [Gastrointestinal Stromal Tumors](https://www.nccn.org/guidelines/guidelines-detail?category=1&id=1507) | 1.2025 | 胃肠道间质瘤 |
| 21 | [Gestational Trophoblastic Neoplasia](https://www.nccn.org/guidelines/guidelines-detail?category=1&id=1489) | 3.2025 | 妊娠滋养细胞肿瘤 |
| 22 | [Hairy Cell Leukemia](https://www.nccn.org/guidelines/guidelines-detail?category=1&id=1481) | 1.2026 | 毛细胞白血病 |
| 23 | [Head and Neck Cancers](https://www.nccn.org/guidelines/guidelines-detail?category=1&id=1437) | 5.2025 | 头颈部癌症 |
| 24 | [Hepatobiliary Cancers](https://www.nccn.org/guidelines/guidelines-detail?category=1&id=1438) | 1.2023 | 肝胆癌症 |
| 25 | [Hepatocellular Carcinoma](https://www.nccn.org/guidelines/guidelines-detail?category=1&id=1514) | 1.2025 | 肝细胞癌 |
| 26 | [Histiocytic Neoplasms](https://www.nccn.org/guidelines/guidelines-detail?category=1&id=1502) | 1.2025 | 组织细胞肿瘤 |
| 27 | [Hodgkin Lymphoma](https://www.nccn.org/guidelines/guidelines-detail?category=1&id=1439) | 2.2025 | 霍奇金淋巴瘤 |
| 28 | [Kaposi Sarcoma](https://www.nccn.org/guidelines/guidelines-detail?category=1&id=1485) | 2.2026 | 卡波西肉瘤 |
| 29 | [Kidney Cancer](https://www.nccn.org/guidelines/guidelines-detail?category=1&id=1440) | 1.2026 | 肾癌 |
| 30 | [Melanoma: Cutaneous](https://www.nccn.org/guidelines/guidelines-detail?category=1&id=1492) | 2.2025 | 皮肤黑色素瘤 |
| 31 | [Melanoma: Uveal](https://www.nccn.org/guidelines/guidelines-detail?category=1&id=1488) | 1.2025 | 葡萄膜黑色素瘤 |
| 32 | [Merkel Cell Carcinoma](https://www.nccn.org/guidelines/guidelines-detail?category=1&id=1444) | 1.2026 | 默克尔细胞癌 |
| 33 | [Mesothelioma: Peritoneal](https://www.nccn.org/guidelines/guidelines-detail?category=1&id=1513) | 2.2025 | 腹膜间皮瘤 |
| 34 | [Mesothelioma: Pleural](https://www.nccn.org/guidelines/guidelines-detail?category=1&id=1512) | 2.2025 | 胸膜间皮瘤 |
| 35 | [Multiple Myeloma](https://www.nccn.org/guidelines/guidelines-detail?category=1&id=1445) | 2.2026 | 多发性骨髓瘤 |
| 36 | [Myelodysplastic Syndromes](https://www.nccn.org/guidelines/guidelines-detail?category=1&id=1446) | 2.2025 | 骨髓增生异常综合征 |
| 37 | [Myeloid/Lymphoid Neoplasms with Eosinophilia and Tyrosine Kinase Gene Fusions](https://www.nccn.org/guidelines/guidelines-detail?category=1&id=1505) | 2.2025 | 伴嗜酸性粒细胞增多和酪氨酸激酶基因融合的髓系/淋巴系肿瘤 |
| 38 | [Myeloproliferative Neoplasms](https://www.nccn.org/guidelines/guidelines-detail?category=1&id=1477) | 2.2025 | 骨髓增殖性肿瘤 |
| 39 | [Neuroblastoma](https://www.nccn.org/guidelines/guidelines-detail?category=1&id=1520) | 1.2025 | 神经母细胞瘤 |
| 40 | [Neuroendocrine and Adrenal Tumors](https://www.nccn.org/guidelines/guidelines-detail?category=1&id=1448) | 2.2025 | 神经内分泌和肾上腺肿瘤 |
| 41 | [Non-Small Cell Lung Cancer](https://www.nccn.org/guidelines/guidelines-detail?category=1&id=1450) | 8.2025 | 非小细胞肺癌 |
| 42 | [Occult Primary](https://www.nccn.org/guidelines/guidelines-detail?category=1&id=1451) | 2.2025 | 隐匿性原发癌 |
| 43 | [Ovarian Cancer/Fallopian Tube Cancer/Primary Peritoneal Cancer](https://www.nccn.org/guidelines/guidelines-detail?category=1&id=1453) | 3.2025 | 卵巢癌/输卵管癌/原发性腹膜癌 |
| 44 | [Pancreatic Adenocarcinoma](https://www.nccn.org/guidelines/guidelines-detail?category=1&id=1455) | 2.2025 | 胰腺腺癌 |
| 45 | [Pediatric Acute Lymphoblastic Leukemia](https://www.nccn.org/guidelines/guidelines-detail?category=1&id=1496) | 1.2026 | 儿科急性淋巴细胞白血病 |
| 46 | [Pediatric Aggressive Mature B-Cell Lymphomas](https://www.nccn.org/guidelines/guidelines-detail?category=1&id=1504) | 2.2025 | 儿科侵袭性成熟B细胞淋巴瘤 |
| 47 | [Pediatric Central Nervous System Cancers](https://www.nccn.org/guidelines/guidelines-detail?category=1&id=1509) | 3.2025 | 儿科中枢神经系统癌症 |
| 48 | [Pediatric Hodgkin Lymphoma](https://www.nccn.org/guidelines/guidelines-detail?category=1&id=1498) | 2.2025 | 儿科霍奇金淋巴瘤 |
| 49 | [Penile Cancer](https://www.nccn.org/guidelines/guidelines-detail?category=1&id=1456) | 2.2025 | 阴茎癌 |
| 50 | [Primary Cutaneous Lymphomas](https://www.nccn.org/guidelines/guidelines-detail?category=1&id=1491) | 3.2025 | 原发性皮肤淋巴瘤 |
| 51 | [Prostate Cancer](https://www.nccn.org/guidelines/guidelines-detail?category=1&id=1459) | 2.2026 | 前列腺癌 |
| 52 | [Rectal Cancer](https://www.nccn.org/guidelines/guidelines-detail?category=1&id=1461) | 3.2025 | 直肠癌 |
| 53 | [Small Bowel Adenocarcinoma](https://www.nccn.org/guidelines/guidelines-detail?category=1&id=1495) | 3.2025 | 小肠腺癌 |
| 54 | [Small Cell Lung Cancer](https://www.nccn.org/guidelines/guidelines-detail?category=1&id=1462) | 2.2026 | 小细胞肺癌 |
| 55 | [Soft Tissue Sarcoma](https://www.nccn.org/guidelines/guidelines-detail?category=1&id=1464) | 1.2025 | 软组织肉瘤 |
| 56 | [Squamous Cell Skin Cancer](https://www.nccn.org/guidelines/guidelines-detail?category=1&id=1465) | 1.2026 | 鳞状细胞皮肤癌 |
| 57 | [Systemic Light Chain Amyloidosis](https://www.nccn.org/guidelines/guidelines-detail?category=1&id=1467) | 1.2026 | 系统性轻链淀粉样变性 |
| 58 | [Systemic Mastocytosis](https://www.nccn.org/guidelines/guidelines-detail?category=1&id=1490) | 1.2025 | 系统性肥大细胞增生症 |
| 59 | [T-Cell Lymphomas](https://www.nccn.org/guidelines/guidelines-detail?category=1&id=1483) | 2.2025 | T细胞淋巴瘤 |
| 60 | [Testicular Cancer](https://www.nccn.org/guidelines/guidelines-detail?category=1&id=1468) | 2.2025 | 睾丸癌 |
| 61 | [Thymomas and Thymic Carcinomas](https://www.nccn.org/guidelines/guidelines-detail?category=1&id=1469) | 2.2025 | 胸腺瘤和胸腺癌 |
| 62 | [Thyroid Carcinoma](https://www.nccn.org/guidelines/guidelines-detail?category=1&id=1470) | 1.2025 | 甲状腺癌 |
| 63 | [Uterine Neoplasms](https://www.nccn.org/guidelines/guidelines-detail?category=1&id=1473) | 3.2025 | 子宫肿瘤 |
| 64 | [Vaginal Cancer](https://www.nccn.org/guidelines/guidelines-detail?category=1&id=1521) | 5.2025 | 阴道癌 |
| 65 | [Vulvar Cancer](https://www.nccn.org/guidelines/guidelines-detail?category=1&id=1476) | 1.2025 | 外阴癌 |
| 66 | [Waldenström Macroglobulinemia/Lymphoplasmacytic Lymphoma](https://www.nccn.org/guidelines/guidelines-detail?category=1&id=1475) | 1.2026 | 华氏巨球蛋白血症/淋巴浆细胞淋巴瘤 |
| 67 | [Wilms Tumor (Nephroblastoma)](https://www.nccn.org/guidelines/guidelines-detail?category=1&id=1500) | 2.2025 | 肾母细胞瘤 |

---

**版权声明：** NCCN指南版权归NCCN所有。保留所有权利。未经NCCN明确书面许可，不得以任何形式、任何目的复制NCCN指南和插图（包括算法）。